Next Article in Journal
Evaluation of β-Lactamase Enzyme Activity in Outer Membrane Vesicles (OMVs) Isolated from Extended Spectrum β-Lactamase (ESBL) Salmonella Infantis Strains
Next Article in Special Issue
Detection of Potential Zoonotic Agents Isolated in Italian Shelters and the Assessment of Animal Welfare Correlation with Antimicrobial Resistance in Escherichia coli Strains
Previous Article in Journal
The Behavior of Some Bacterial Strains Isolated from Fallow Deer Compared to Antimicrobial Substances in Western Romania
Previous Article in Special Issue
Personal Care Products as a Contributing Factor to Antimicrobial Resistance: Current State and Novel Approach to Investigation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 12
Issue 4
10.3390/antibiotics12040745
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Prevalence and Characterization of Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolated from Dogs and Cats in South Korea

by
Ji-Hyun Choi
1,
Md. Sekendar Ali
1,
Bo-Youn Moon
1,
Hee-Young Kang
1,
Su-Jeong Kim
1,
Hyun-Ju Song
1,
Abraham Fikru Mechesso
2,
Dong-Chan Moon
3,* and
Suk-Kyung Lim
1,*
1
Bacterial Disease Division, Animal and Plant Quarantine Agency, 177 Hyeksin 8-ro, Gimcheon-si 39660, Republic of Korea
2
Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198-5900, USA
3
Division of Antimicrobial Resistance Research, Center for Infectious Diseases Research, Korea Disease Control and Prevention Agency, Cheongju 28159, Republic of Korea
*
Authors to whom correspondence should be addressed.
Antibiotics 2023, 12(4), 745; https://doi.org/10.3390/antibiotics12040745
Submission received: 15 March 2023 / Revised: 7 April 2023 / Accepted: 9 April 2023 / Published: 13 April 2023
(This article belongs to the Special Issue Antimicrobial Resistance in One Health Perspective: New Insights in Human, Animal, and Environment Interlace)
Browse Figures
Versions Notes

Abstract

:
Overall, 836 Escherichia coli isolates (695 isolates from dogs and 141 from cats) were recovered from the diarrhea, skin/ear, urine, and genitals of dogs and cats between 2018 and 2019. Cefovecin and enrofloxacin resistance were noted in 17.1% and 21.2% of E. coli isolates, respectively. The cefovecin and enrofloxacin resistance rates were higher in dog isolates (18.1% and 22.9%) compared with the rates in cat isolates (12.1%, 12.8%). Interestingly, resistance to both antimicrobials was noted in 10.8% (90/836) of the isolates, predominantly in isolates from dogs. blaCTX-M-14, blaCTX-M-15, and blaCMY-2 were the most frequent extended-spectrum β-lactamase/plasmid-mediated AmpC β-lactamase (ESBL/AmpC)- gene types. The co-existence of blaCTX-M and blaCMY-2 was noted in six E. coli isolates from dogs. Sequencing analysis demonstrated that S83L and D87N in gyrA and S80I in parC were the most frequent point mutations in the quinolone resistance-determining regions of the cefovecin and enrofloxacin-resistant isolates. A total of 11 isolates from dogs carried the plasmid-mediated quinolone resistance genes (six aac(6’)-Ib-cr, four qnrS, and one qnrB), while only two cat isolates carried the qnrS gene. Multilocus sequence typing of the cefovecin and enrofloxacin-resistant isolates revealed that sequence type (ST)131 E. coli carrying blaCTX-M-14 and blaCTX-M-15 genes and ST405 E. coli carrying blaCMY-2 gene were predominant among the isolated E. coli strains. The majority of the ESBL/AmpC-producing isolates displayed diverse pulsed-field gel electrophoresis profiles. This study demonstrated that third-generation cephalosporin- and fluoroquinolone-resistant E. coli were widely distributed in companion animals. The detection of the pandemic ST131 clone carrying blaCTX-M-14/15 in companion animals presented a public health threat.

1. Introduction

Escherichia coli is a Gram-negative, rod-shaped facultative commensal bacterium commonly found in the gastrointestinal tract of humans and warm-blooded animals and rarely causes diseases. However, some strains have acquired genes that enable them to cause intestinal and extraintestinal infections. The most common strains associated with intestinal infections include enteropathogenic, enterotoxigenic, enteroinvasive, enteroaggregative, and enterohemorrhagic E. coli [1]. The disruption of normal intestinal anatomic barriers and subsequent spread of E. coli to adjacent tissue structures or the bloodstream could lead to extraintestinal infections such as urinary tract infections, meningitis, septicemia, and skin infections, especially in immunocompromised individuals [1,2,3].
Fluoroquinolones and third-generation cephalosporins are among the clinically important antimicrobials for the treatment of E. coli infection. However, the overuse or misuse of these antimicrobials in humans and companion animals has contributed to the emergence of cephalosporin- and fluoroquinolones-resistant strains. Alarmingly, the occurrence of E. coli co-resistant to these antimicrobials could lead to failure of treatment for serious infection in humans and companion animals [4,5].
Extended-spectrum β-lactamase (ESBL) and/or plasmid-mediated AmpC β-lactamase (pAmpC)-producing E. coli have been identified in companion animals worldwide [6,7]. In South Korea, we identified blaCTX-M-14 -carrying E. coli from a diseased dog for the first time in 2009 [8]. Since then, various ESBL and AmpC-producing E. coli have been isolated from companion animals [9,10]. The frequent and direct interactions between humans and companion animals may play a significant role in the dissemination of ESBL and AmpC-producing E. coli [11]. Therefore, this study aimed to determine the prevalence of third-generation cephalosporins and fluoroquinolone resistance in E. coli isolated from dogs and cats. Further investigations were also conducted to determine the molecular characteristics of ESBL and/or AmpC-producing E. coli.

2. Results

2.1. Prevalence of Cefovecin and Enrofloxacin Resistance

A total of 836 E. coli isolates were obtained from dogs (695) and cats (141) (Table 1). The overall cefovecin and enrofloxacin resistance rates were 17.1% and 21.2%, respectively. Cefovecin and enrofloxacin resistance rates in dog isolates (18.1% and 22.9%) were significantly higher than that of cat isolates (12.1% and 12.8%) (p < 0.05). E. coli isolated from the skin/ear and urine of dogs and cats exhibited relatively high resistance rates to cefovecin (24.2–25%) and enrofloxacin (23.4–34.1%). Cefovecin and enrofloxacin resistance varied with age groups. A relatively high resistance rate to these antimicrobials was found in isolates from dogs aged 11–15 years, followed by those from <1 year and 6–10 years age groups (Table 2). However, almost all of the cefovecin and enrofloxacin-resistant isolates from cats were identified from those aged <6 years. Generally, although the number of isolates from older animals (≥15 years) was fewer than those isolated from younger (≤5 years) age groups, cefovecin and enrofloxacin resistance rates were relatively high in isolates from adult animals (aged 11–15 years) compared with those from younger animals.

2.2. Distribution and Characterization of ESBL/AmpC-Producing E. coli

We selected 89 cefovecin and enrofloxacin-resistant isolates (70 from dogs and 11 from cats) for further assessment of ESBL/AmpC-production (Table 3). We identified five different types of blaCTX-M types (blaCTX-M-3, blaCTX-M-14, blaCTX-M-15, blaCTX-M-55, and blaCTX-M-65) and two AmpC types (blaCMY-2 and blaDHA). blaCTX-M-14 and blaCTX-M-15-carrying isolates comprised the majority (73.2%, 41/56) of the blaCTX-M types. Most of the blaCTX-M -carrying isolates from dogs and all of the blaCTX-M-carrying isolates from cats were obtained from fecal samples. Indeed, only a very few blaCTX-M-3 and blaCTX-M-55 carrying isolates were found among isolates from urine samples of dogs. In addition, blaCMY-2 was detected in all AmpC-producing isolates, while blaDHA was detected only in one isolate. Interestingly, the co-occurrence of blaCTX-M and blaCMY genes was noted in six dog isolates.

2.3. Mechanisms of Quinolone Resistance

Sequencing analysis demonstrated that all the 89 cefovecin and enrofloxacin-resistant isolates possessed at least one mutation in the quinolone resistance-determining region (QRDR) (Table 4). The most frequently observed mutations in both dog and cat isolates were S83L and D87N in gyrA and S80I in parC. In addition, a total of 11 dog isolates carried the qnr genes (six aac(6’)-Ib-cr, four qnrS, and one qnrB), while only two cat isolates carried qnrS. Interestingly, qnr gene carriage did not cause a significant difference in fluoroquinolone MICs.

2.4. Molecular Characterization

Multi-locus sequence typing (MLST) revealed 25 STs, with 23 types in 78 dog isolates and 7 types in 11 cat isolates (Table 5). ST131 was the predominant ST in dog isolates followed by ST405, ST457, and ST38. ST131 E. coli was widely distributed in twelve hospitals that were located in six cities. The most predominant STs among cat isolates were ST405 and ST648. PFGE analysis revealed that all the ST131 E. coli isolates from dogs showed distinct PFGE profiles (40–80% similarity), indicating genetic variability among the isolates. Notably, four blaCMY-2-carrying ST405 E. coli from dogs and cats from different hospitals in Seoul and Incheon cities presented identical PFGE patterns (Figure 1).

3. Discussion

In this study, a significant proportion of E. coli isolated from diseased dogs and cats in Korea was identified as ESBL/AmpC-producers, and blaCTX-M- and/or blaCMY-2 -carrying isolates were further characterized using molecular techniques.
Third-generation cephalosporin-resistant isolates are regarded as a potential hazard to both animal and human health because they frequently exhibit multidrug resistance to clinically important antimicrobials [12]. In the present study, 18.1% and 12.1% of the E. coli isolated from dogs and cats were resistant to cefovecin. The cefovecin resistance rate in this study agreed with earlier studies from Hong Kong (20%) [13] and Australia (17%) [14]. However, it was lower than other reports in the UK (31%) [15] and Poland (28%) [16]. Interestingly, we identified a relatively high third-generation cephalosporin resistance in isolates from urine and skin/ear samples. This could be associated with the frequent use of these antimicrobials for the treatment of dermatitis and urinary tract infections in companion animals. A recent study has also shown the link between the use of third-generation cephalosporins and emergence of resistance to one or more of these antimicrobials in companion animals [17]. The high prevalence of fluoroquinolone-resistant E. coli among companion animals and humans is still a matter of concern [18].
In this study, the enrofloxacin resistance rate in dog isolates (23.2%) was almost twice the rate in cat (12.8%) isolates. This finding concurred with previous reports in France (19%) [19], South Africa (16%) [20], and the USA (16%) [21]. However, it was lower than those reported in China (61%) [22], Japan (40%) [23], and Greece (39%) [24]. The fluoroquinolone resistance is linked with mutations in topoisomerases or acquisition of plasmid-mediated quinolone resistance genes [25].
Resistance to multiple critically important antimicrobials poses significant public health concerns. In this study, about 11% of E. coli isolates were resistant to cefovecin and enrofloxacin. Resistance to both antimicrobials in E. coli isolated from companion animals has been reported in Korea [26] and other countries [27,28]. The frequent application of fluoroquinolones and third-generation cephalosporins in companion animals could lead to the emergence of Enterobacteriaceae resistant to both antimicrobials [29]. In addition, fluoroquinolone resistance in E. coli might trigger resistance to third-generation cephalosporins [5,28]. Previous studies showed that resistance to extended-spectrum cephalosporins and fluoroquinolones could also occur in other Gram-negative Enterobacteriaceae, such as Klebsiella spp. [30,31,32]. Klebsiella pneumoniae isolated from humans and companion animals can produce β-lactamase, making cephalosporin ineffective by hydrolyzing the β-lactam ring [10,33]. This extended-spectrum cephalosporin-resistant Enterobacteriaceae can directly spread and distribute between humans and companion animals [11].
It has been shown that age is an important factor in the development of bacterial infection and the emergence of antimicrobial resistance [34]. However, only limited reports are available on the prevalence of antimicrobial resistance in bacteria isolated from companion animals of different age groups. In agreement with Schwartz et al. [35], this study showed that cefovecin and enrofloxacin resistance rates were high in isolates identified from relatively old dogs (aged 11–15 years), providing evidence for the occurrence of antimicrobial resistance traits in isolates from relatively older age groups of animals. In contrast, some previously published data showed inconsistent resistance dynamics in isolates from animals of different age groups [36].
Diverse ESBL/AmpC-encoding genes have been detected in bacteria isolated from companion animals worldwide. In this study, the blaCTX-M-14 and blaCTX-M-15 genes were the most frequent ESBL genes in both dog and cat isolates. These genes were frequently reported in humans and companion animals in Korea [9]. In addition, blaCMY-2 was identified in 43.8% of E. coli isolated from dogs and cats. This gene was frequently detected in cephamycin-resistant E. coli recovered from humans and animals in many countries [31,37]. Notably, plasmids bearing the blaCMY-2 gene have also been reported in clinical and community isolates in humans in Korea [37]. These results emphasize the necessity of coordinated control of ESBL/AmpC-producing E. coli in humans and companion animals.
Mutations in gyrA and parC genes have been linked with high fluoroquinolone resistance [38]. In this study, we identified mutations in gyrA and parC genes in fluoroquinolone-resistant E. coli isolated from dogs and cats. The most common mutations were S83L and D87N in gyrA and S80I in parC. Hopkins et al. [39] also demonstrated that codons 83 and 87 of gyrA and codon 80 of parC were the most frequent mutation sites in gyrA and parC. In this study, about 14% of the enrofloxacin-resistant isolates harbor at least one PMQR gene, with qnrB, qnrS, and aac(6′)-Ib-cr being detected alone or in combination. Agreeing with this study, E. coli isolated from humans and companion animals have frequently been observed to carry qnr [28,40,41] and aac(6’)-Ib-cr [38,40,41,42,43] genes. In addition, all the enrofloxacin-resistant E. coli isolates exhibited high levels of resistance (MIC ≥ 16 mg/L), regardless of qnr gene carriage. Therefore, fluoroquinolone resistance in these isolates could be associated with the carriage of one or more PMQR-encoding genes as well as mutations in the QRDR [44]. Particularly, the co-occurrence of PMQR and blaCTX-M and/or blaCMY-2 genes in isolates from companion animals constitutes a public health concern.
MLST is useful for assessing major changes of the lineages among isolates and understanding global epidemiology [45]. We observed 25 different E. coli STs, of which 23 were from dogs and 7 were from cats. Four of the STs (ST648, ST457, ST357, and ST405) were found in both dogs and cats. In this study, isolates belonging to diverse STs were recovered from most of the cities. This might be associated with the widespread distribution of some clones (ST131 and ST38) in Korea or due to the visits of animals to hospitals in different cities. Additionally, E. coli ST131 isolates were frequently detected in dogs from different animal hospitals in four cities. E. coli ST131 is a multidrug-resistant pandemic clone found in humans and companion animals [46,47]. This clone is responsible for various infections in humans [47,48]. Interestingly, this ST131 E. coli isolate was frequently reported to carry blaCTX-M-15 in many countries [49]. In Korea, blaCTX-M-15 carrying ST131 E. coli has been associated with a variety of invasive infections in humans [50]. The frequent contact between humans and companion animals necessities further studies on clonal relatedness between isolates from humans and companion animals. PFGE analysis showed that the blaCTX-M-carrying ST131 E. coli presented diverse patterns in dogs, which implies that most of the isolates acquired resistance individually. In contrast, a few blaCMY-2-carrying ST405 strains of dogs and cats exhibited similar PFGE patterns. This could be due to cross-contamination in the animal shelter or hospitals and/or staff or material movement within the same facility.
This study provides important insights into mechanisms of resistance and molecular profiles of cephalosporin and fluoroquinolone-resistant E. coli resistant strains isolated from companion animals. Since E. coli that carry resistance to clinically important antimicrobials can be transmitted between humans and companion animals, it is crucial to establish prevention and control strategies in veterinary practice settings. Furthermore, addressing concerns about the potential transmission of these infections to humans is of utmost importance.

4. Materials and Methods

4.1. Sample Collection

E. coli isolates were collected from seven different laboratories/centers participating in the Korean Veterinary Antimicrobial Resistance Monitoring System from 2018 to 2019. The isolates were recovered from the diarrhea, skin, ear canals, urine, and genitalia of dogs and cats. Samples were placed on ice and transported to the laboratories/centers within 6 h of collection. The number of isolates collected from different veterinary hospitals in each city is shown in Figure 2. However, the authors do not have information about the history of antimicrobial use in dogs and cats, and the number of samples considered for this study.

4.2. E. coli Isolation

Isolation and identification of E. coli were performed as described in our previous reports [51,52]. Briefly, swab samples were streaked on Eosin Methylene Blue (EMB) agar (Becton Dickinson, Sparks, NV, USA) and incubated at 37 °C for 24 h. Then, three suspected colonies were sub-cultured on MacConkey agar plates (MAC, BD, Spark, Baltimore, MD, USA) and incubated overnight at 37 ℃ for 24 h. Isolates were then confirmed by matrix-assisted laser desorption and ionization-time-of-flight mass spectrometry (MALDI-TOF, Biomerieux, Marcy L’Etoile, France). Only a single isolate per sample was considered for further assay [52].

4.3. Antimicrobial Susceptibility Testing

The antimicrobial susceptibility profiles of the isolates were determined by the broth microdilution methods based on the Clinical and Laboratory Standards Institute (CLSI) guidelines [53], using commercially available Sensititre plates COMPGN1F (Thermo Trek Diagnostics, Waltham, MA, USA). The isolates were tested for susceptibility toward ciprofloxacin, enrofloxacin, marbofloxacin, nalidixic acid, and ofloxacin. E. coli ATCC25922 was used as a quality reference strain. The results were interpreted according to the CLSI guidelines [53].

4.4. Mechanisms of Antimicrobial Resistance

A polymerase chain reaction (PCR) assay was performed to detect the presence of blaCTX-M and AmpC genes using the previously described primers (Supplementary Material Table S1) [12]. Sequence analysis was performed using ABI3730XL DNA sequence analyzer (SolGent, Daejeon, Republic of Korea) and comparison with known sequences was performed with the Basic Local Alignment Search Tool (BLAST) programs at the National Center for Biotechnology Information website (www.ncbi.nim.nih.gov/BLAST, accessed on 10 August 2022). Multiplex PCR was used to detect plasmid-mediated quinolone resistance (PMQR) genes such as qnrB, qnrS, and aac(6’)-Ib-cr using conditions and primers described previously (Table S1) [12]. In addition, the quinolone resistance-determining regions (QRDR) of gyrA and parC were amplified using primers described previously (Table S1) [54]. Following that, the purified PCR products were sequenced by an automated ABI prism 3700 analyzer (Applied Biosystems, Foster City, CA, USA) and compared to those of standard E. coli K-12 strain using the BLAST and exPASY proteomics tools (www.expasy.ch/tools/similarity, accessed on 10 August 2022).

4.5. Molecular Characterization

Multi-locus sequencing typing (MLST) was carried out to investigate the clonal relationship of the cefovecin- and enrofloxacin-resistant isolates according to the previously described method [55]. The following six housekeeping genes were amplified and sequenced using specific primers: adk, fumC, gyrB, icd, mdh, purA, and recA. Allelic profile and sequence types (STs) were determined using web-based MLST databases for E. coli (https://pubmlst.org/databases/, accessed on 12 September 2022). In addition, the genetic diversity of the ESBL/AmpC-producing isolates was assessed by pulsed-field gel electrophoresis (PFGE) of chromosomal DNA digested with XbaI (Takara Inc., Shiga, Japan) [56]. The relatedness of the isolates was then determined using the unweighted pair group approach with the arithmetic average algorithm (UPGMA) based on the Dice similarity index (Bionumerics software, version 4.0; Applied Maths, Sint-Martens-Latem, Belgium).

4.6. Statistical Analysis

The statistical analysis was performed using the SPSS software (version 25, Armonk, NY, USA), which included the independent samples t-test, Fisher’s exact test, and chi-square test. p-Values < 0.05 were considered statistically significant.

5. Conclusions and Future Perspectives

The current study demonstrated that E. coli isolated from companion animals (dogs and cats) exhibited resistance to cefovecin and enrofloxacin. ESBL/AmpC-producing E. coli carried predominantly blaCTX-M-14, blaCTX-M-15, and blaCMY-2 genes. Fluoroquinolone-resistant isolates frequently possessed S83L and D87N mutations in QRDR of gyrA and parC as well as carry PMQR genes (aac(6’)-Ib-cr, qnrS, and qnrB). Particularly, blaCTX-M-15-carrying pandemic E. coli ST131 strain was most frequent among E. coli isolated from dogs. The study limitations include the absence of data on the number of samples by sex and season and the severity of the animals’ ailment. However, this study provides useful insight into third-generation cephalosporin and fluoroquinolones resistance in companion animals. Therefore, long-term surveillance of resistance patterns and judicious selection of antimicrobials is required to prevent the spread and evolution of antibiotic-resistant E. coli among humans and companion animals.

Supplementary Materials

The following supplementary materials are available at https://www.mdpi.com/article/10.3390/antibiotics12040745/s1, Table S1: Lists of primer sequences and PCR conditions. References [57,58,59,60,61,62,63] are cited in the supplementary materials.

Author Contributions

Conceptualization, S.-K.L. and D.-C.M.; methodology, J.-H.C., H.-Y.K. and D.-C.M.; software, D.-C.M., B.-Y.M. and J.-H.C.; validation, M.S.A. and S.-K.L.; formal analysis, S.-K.L., H.-J.S., M.S.A. and S.-J.K.; investigation, S.-K.L., D.-C.M., J.-H.C., H.-Y.K., S.-J.K. and H.-J.S.; resources, S.-K.L.; data curation, D.-C.M., A.F.M. and S.-K.L.; writing—original draft preparation, J.-H.C. and M.S.A.; writing—review and editing, B.-Y.M., M.S.A., A.F.M. and D.-C.M.; visualization, S.-K.L.; supervision, D.-C.M. and S.-K.L.; project administration, S.-K.L. and D.-C.M.; funding acquisition, D.-C.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Animal and Plant Quarantine Agency, Ministry of Agriculture, Food, and Rural Affairs (grant no. N-1543081-2017-24-01).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

All data generated for this study are contained within the article.

Acknowledgments

We are grateful to the staff of the laboratories/centers participating in the Korean Veterinary Antimicrobial Resistance Monitoring System from 2018 to 2019.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Robins-Browne, R.M.; Holt, K.E.; Ingle, D.J.; Hocking, D.M.; Yang, J.; Tauschek, M. Are Escherichia coli Pathotypes Still Relevant in the Era of Whole-Genome Sequencing? Front. Cell. Infect. Microbiol. 2016, 6, 141. [Google Scholar] [CrossRef] [Green Version]
  2. Díaz-Jiménez, D.; García-Meniño, I.; Herrera, A.; García, V.; López-Beceiro, A.M.; Alonso, M.P.; Blanco, J.; Mora, A. Genomic Characterization of Escherichia coli Isolates Belonging to a New Hybrid AEPEC/ExPEC Pathotype O153: H10-A-ST10 Eae-Beta1 Occurred in Meat, Poultry, Wildlife and Human Diarrheagenic Samples. Antibiotics 2020, 9, 192. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Bélanger, L.; Garenaux, A.; Harel, J.; Boulianne, M.; Nadeau, E.; Dozois, C.M. Escherichia coli from Animal Reservoirs as a Potential Source of Human Extraintestinal Pathogenic E. coli. FEMS Immunol. Med. Microbiol. 2011, 62, 1–10. [Google Scholar] [CrossRef] [Green Version]
  4. Seni, J.; Falgenhauer, L.; Simeo, N.; Mirambo, M.M.; Imirzalioglu, C.; Matee, M.; Rweyemamu, M.; Chakraborty, T.; Mshana, S.E. Multiple ESBL-Producing Escherichia coli Sequence Types Carrying Quinolone and Aminoglycoside Resistance Genes Circulating in Companion and Domestic Farm Animals in Mwanza, Tanzania, Harbor Commonly Occurring Plasmids. Front. Microbiol. 2016, 7, 142. [Google Scholar] [CrossRef] [Green Version]
  5. Han, C.; Yang, Y.; Wang, M.; Wang, A.; Lu, Q.; Xu, X.; Wang, C.; Liu, L.; Deng, Q.; Shen, X. The Prevalence of Plasmid-Mediated Quinolone Resistance Determinants among Clinical Isolates of ESBL or AmpC-Producing Escherichia coli from Chinese Pediatric Patients. Microbiol. Immunol. 2010, 54, 123–128. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Barguigua, A.; El Otmani, F.; Talmi, M.; Zerouali, K.; Timinouni, M. Prevalence and Types of Extended Spectrum β-Lactamases among Urinary Escherichia coli Isolates in Moroccan Community. Microb. Pathog. 2013, 61, 16–22. [Google Scholar] [CrossRef] [PubMed]
  7. Belmahdi, M.; Bakour, S.; Al Bayssari, C.; Touati, A.; Rolain, J.-M. Molecular Characterisation of Extended-Spectrum β-Lactamase-and Plasmid AmpC-Producing Escherichia coli Strains Isolated from Broilers in Béjaïa, Algeria. J. Glob. Antimicrob. Resist. 2016, 6, 108–112. [Google Scholar] [CrossRef] [PubMed]
  8. Lim, S.-K.; Lee, H.-S.; Nam, H.-M.; Jung, S.-C.; Bae, Y. CTX-M-Type β-Lactamase in Escherichia coli Isolated from Sick Animals in Korea. Microb. Drug Resist. 2009, 15, 139–142. [Google Scholar] [CrossRef]
  9. Choi, M.J.; Lim, S.K.; Jung, S.C.; Ko, K.S. Comparisons of CTX-M-Producing Escherichia coli Isolates from Humans and Animals in South Korea. J. Bacteriol. Virol. 2014, 44, 44–51. [Google Scholar] [CrossRef] [Green Version]
  10. Shin, S.R.; Noh, S.M.; Jung, W.K.; Shin, S.; Park, Y.K.; Moon, D.C.; Lim, S.-K.; Park, Y.H.; Park, K.T. Characterization of Extended-Spectrum β-Lactamase-Producing and AmpC β-Lactamase-Producing Enterobacterales Isolated from Companion Animals in Korea. Antibiotics 2021, 10, 249. [Google Scholar] [CrossRef]
  11. Hong, J.S.; Song, W.; Park, H.-M.; Oh, J.-Y.; Chae, J.-C.; Shin, S.; Jeong, S.H. Clonal Spread of Extended-Spectrum Cephalosporin-Resistant Enterobacteriaceae between Companion Animals and Humans in South Korea. Front. Microbiol. 2019, 10, 1371. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Song, H.-J.; Moon, D.C.; Mechesso, A.F.; Kang, H.Y.; Kim, M.H.; Choi, J.-H.; Kim, S.-J.; Yoon, S.-S.; Lim, S.-K. Resistance Profiling and Molecular Characterization of Extended-Spectrum/Plasmid-Mediated Ampc β-Lactamase-Producing Escherichia coli Isolated from Healthy Broiler Chickens in South Korea. Microorganisms 2020, 8, 1434. [Google Scholar] [CrossRef] [PubMed]
  13. Chan, O.S.K.; Baranger-Ete, M.; Lam, W.W.T.; Wu, P.; Yeung, M.; Lee, E.; Bond, H.; Swan, O.; Tun, H.M. A Retrospective Study of Antimicrobial Resistant Bacteria Associated with Feline and Canine Urinary Tract Infection in Hong Kong SAR, China-A Case Study on Implication of First-Line Antibiotics Use. Antibiotics 2022, 11, 1140. [Google Scholar] [CrossRef]
  14. Saputra, S.; Jordan, D.; Mitchell, T.; San Wong, H.; Abraham, R.J.; Kidsley, A.; Turnidge, J.; Trott, D.J.; Abraham, S. Antimicrobial Resistance in Clinical Escherichia coli Isolated from Companion Animals in Australia. Vet. Microbiol. 2017, 211, 43–50. [Google Scholar] [CrossRef] [Green Version]
  15. Fonseca, J.D.; Mavrides, D.E.; Graham, P.A.; McHugh, T.D. Results of Urinary Bacterial Cultures and Antibiotic Susceptibility Testing of Dogs and Cats in the UK. J. Small Anim. Pract. 2021, 62, 1085–1091. [Google Scholar] [CrossRef]
  16. Rzewuska, M.; Czopowicz, M.; Kizerwetter-Świda, M.; Chrobak, D.; Błaszczak, B.; Binek, M. Multidrug Resistance in Escherichia coli Strains Isolated from Infections in Dogs and Cats in Poland (2007–2013). Sci. World J. 2015, 2015, 408205. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Marco-Fuertes, A.; Marin, C.; Lorenzo-Rebenaque, L.; Vega, S.; Montoro-Dasi, L. Antimicrobial Resistance in Companion Animals: A New Challenge for the One Health Approach in the European Union. Vet. Sci. 2022, 9, 208. [Google Scholar] [CrossRef] [PubMed]
  18. Sato, T.; Yokota, S.; Ichihashi, R.; Miyauchi, T.; Okubo, T.; Usui, M.; Fujii, N.; Tamura, Y. Isolation of Escherichia coli Strains with AcrAB–TolC Efflux Pump-Associated Intermediate Interpretation or Resistance to Fluoroquinolone, Chloramphenicol, and Aminopenicillin from Dogs Admitted to a University Veterinary Hospital. J. Vet. Med. Sci. 2014, 76, 937–945. [Google Scholar] [CrossRef] [Green Version]
  19. Bourély, C.; Cazeau, G.; Jarrige, N.; Leblond, A.; Madec, J.Y.; Haenni, M.; Gay, E. Antimicrobial Resistance Patterns of Bacteria Isolated from Dogs with Otitis. Epidemiol. Infect. 2019, 147, e121. [Google Scholar] [CrossRef] [Green Version]
  20. Qekwana, D.N.; Phophi, L.; Naidoo, V.; Oguttu, J.W.; Odoi, A. Antimicrobial Resistance among Escherichia coli Isolates from Dogs Presented with Urinary Tract Infections at a Veterinary Teaching Hospital in South Africa. BMC Vet. Res. 2018, 14, 228. [Google Scholar] [CrossRef] [Green Version]
  21. Osman, M.; Albarracin, B.; Altier, C.; Gröhn, Y.T.; Cazer, C. Antimicrobial Resistance Trends among Canine Escherichia coli Isolated at a New York Veterinary Diagnostic Laboratory between 2007 and 2020. Prev. Vet. Med. 2022, 208, 105767. [Google Scholar] [CrossRef] [PubMed]
  22. Liu, X.; Liu, H.; Li, Y.; Hao, C. Association between Virulence Profile and Fluoroquinolone Resistance in Escherichia coli Isolated from Dogs and Cats in China. J. Infect. Dev. Ctries. 2017, 11, 306–313. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Umeda, K.; Hase, A.; Fukuda, A.; Matsuo, M.; Horimoto, T.; Ogasawara, J. Prevalence and Mechanisms of Fluoroquinolone-Resistant Escherichia coli among Sheltered Companion Animals. Access Microbiol. 2020, 2, e000077. [Google Scholar] [CrossRef] [PubMed]
  24. Vingopoulou, E.I.; Delis, G.A.; Batzias, G.C.; Kaltsogianni, F.; Koutinas, A.; Kristo, I.; Pournaras, S.; Saridomichelakis, M.N.; Siarkou, V.I. Prevalence and Mechanisms of Resistance to Fluoroquinolones in Pseudomonas aeruginosa and Escherichia coli Isolates Recovered from Dogs Suffering from Otitis in Greece. Vet. Microbiol. 2018, 213, 102–107. [Google Scholar] [CrossRef]
  25. Morgan-Linnell, S.K.; Becnel Boyd, L.; Steffen, D.; Zechiedrich, L. Mechanisms Accounting for Fluoroquinolone Resistance in Escherichia coli Clinical Isolates. Antimicrob. Agents Chemother. 2009, 53, 235–241. [Google Scholar] [CrossRef] [Green Version]
  26. Tamang, M.D.; Nam, H.-M.; Jang, G.-C.; Kim, S.-R.; Chae, M.H.; Jung, S.-C.; Byun, J.-W.; Park, Y.H.; Lim, S.-K. Molecular Characterization of Extended-Spectrum-β-Lactamase-Producing and Plasmid-Mediated AmpC β-Lactamase-Producing Escherichia coli Isolated from Stray Dogs in South Korea. Antimicrob. Agents Chemother. 2012, 56, 2705–2712. [Google Scholar] [CrossRef] [Green Version]
  27. Adams, R.J.; Kim, S.S.; Mollenkopf, D.F.; Mathys, D.A.; Schuenemann, G.M.; Daniels, J.B.; Wittum, T.E. Antimicrobial-resistant Enterobacteriaceae Recovered from Companion Animal and Livestock Environments. Zoonoses Public Health 2018, 65, 519–527. [Google Scholar] [CrossRef]
  28. Shaheen, B.W.; Nayak, R.; Foley, S.L.; Boothe, D.M. Chromosomal and Plasmid-Mediated Fluoroquinolone Resistance Mechanisms among Broad-Spectrum-Cephalosporin-Resistant Escherichia coli Isolates Recovered from Companion Animals in the USA. J. Antimicrob. Chemother. 2013, 68, 1019–1024. [Google Scholar] [CrossRef] [Green Version]
  29. Asensio, A.; Alvarez-Espejo, T.; Fernandez-Crehuet, J.; Ramos, A.; Vaque-Rafart, J.; Bishopberger, C.; Navarrete, M.J.H.; Calbo-Torrecillas, F.; Campayo, J.; Canton, R.T. Trends in yearly prevalence of third-generation cephalosporin and fluoroquinolone resistant Enterobacteriaceae infections and antimicrobial use in Spanish hospitals, Spain, 1999 to 2010. Eurosurveillance 2011, 16, 19983. [Google Scholar] [CrossRef] [Green Version]
  30. Pai, H.; Seo, M.-R.; Choi, T.Y. Association of QnrB Determinants and Production of Extended-Spectrum β-Lactamases or Plasmid-Mediated AmpC β-Lactamases in Clinical Isolates of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2007, 51, 366–368. [Google Scholar] [CrossRef] [Green Version]
  31. Woodford, N.; Reddy, S.; Fagan, E.J.; Hill, R.L.R.; Hopkins, K.L.; Kaufmann, M.E.; Kistler, J.; Palepou, M.-F.I.; Pike, R.; Ward, M.E.; et al. Wide Geographic Spread of Diverse Acquired AmpC β-Lactamases among Escherichia coli and Klebsiella Spp. in the UK and Ireland. J. Antimicrob. Chemother. 2006, 59, 102–105. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Donati, V.; Feltrin, F.; Hendriksen, R.S.; Svendsen, C.A.; Cordaro, G.; García-Fernández, A.; Lorenzetti, S.; Lorenzetti, R.; Battisti, A.; Franco, A. Extended-Spectrum-Beta-Lactamases, AmpC Beta-Lactamases and Plasmid Mediated Quinolone Resistance in Klebsiella Spp. from Companion Animals in Italy. PLoS ONE 2014, 9, e90564. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Lee, S.-G.; Jeong, S.H.; Lee, H.; Kim, C.K.; Lee, Y.; Koh, E.; Chong, Y.; Lee, K. Spread of CTX-M–Type Extended-Spectrum β-Lactamases among Bloodstream Isolates of Escherichia coli and Klebsiella pneumoniae from a Korean Hospital. Diagn. Microbiol. Infect. Dis. 2009, 63, 76–80. [Google Scholar] [CrossRef] [PubMed]
  34. Hoekstra, K.A.; Paulton, R.J.L. Clinical Prevalence and Antimicrobial Susceptibility of Staphylococcus aureus and Staph. intermedius in Dogs. J. Appl. Microbiol. 2002, 93, 406–413. [Google Scholar] [CrossRef] [PubMed]
  35. Schwarz, S.; Chaslus-Dancla, E. Use of Antimicrobials in Veterinary Medicine and Mechanisms of Resistance. Vet. Res. 2001, 32, 201–225. [Google Scholar] [CrossRef] [Green Version]
  36. Gaire, T.N.; Scott, H.M.; Sellers, L.; Nagaraja, T.G.; Volkova, V.V. Age Dependence of Antimicrobial Resistance among Fecal Bacteria in Animals: A Scoping Review. Front. Vet. Sci. 2021, 7, 622495. [Google Scholar] [CrossRef]
  37. Yoo, J.S.; Byeon, J.; Yang, J.; Yoo, J.I.; Chung, G.T.; Lee, Y.S. High Prevalence of Extended-Spectrum β-Lactamases and Plasmid-Mediated AmpC β-Lactamases in Enterobacteriaceae Isolated from Long-Term Care Facilities in Korea. Diagn. Microbiol. Infect. Dis. 2010, 67, 261–265. [Google Scholar] [CrossRef]
  38. Röderova, M.; Halova, D.; Papousek, I.; Dolejska, M.; Masarikova, M.; Hanulik, V.; Pudova, V.; Broz, P.; Htoutou-Sedlakova, M.; Sauer, P.; et al. Characteristics of Quinolone Resistance in Escherichia coli Isolates from Humans, Animals, and the Environment in the Czech Republic. Front. Microbiol. 2017, 7, 2147. [Google Scholar] [CrossRef] [Green Version]
  39. Hopkins, K.L.; Davies, R.H.; Threlfall, E.J. Mechanisms of Quinolone Resistance in Escherichia coli and Salmonella: Recent Developments. Int. J. Antimicrob. Agents 2005, 25, 358–373. [Google Scholar] [CrossRef]
  40. Gibson, J.S.; Cobbold, R.N.; Kyaw-Tanner, M.T.; Heisig, P.; Trott, D.J. Fluoroquinolone Resistance Mechanisms in Multidrug-Resistant Escherichia coli Isolated from Extraintestinal Infections in Dogs. Vet. Microbiol. 2010, 146, 161–166. [Google Scholar] [CrossRef]
  41. Yang, T.; Zeng, Z.; Rao, L.; Chen, X.; He, D.; Lv, L.; Wang, J.; Zeng, L.; Feng, M.; Liu, J.-H. The Association between Occurrence of Plasmid-Mediated Quinolone Resistance and Ciprofloxacin Resistance in Escherichia coli Isolates of Different Origins. Vet. Microbiol. 2014, 170, 89–96. [Google Scholar] [CrossRef]
  42. de Jong, A.; Muggeo, A.; El Garch, F.; Moyaert, H.; de Champs, C.; Guillard, T. Characterization of Quinolone Resistance Mechanisms in Enterobacteriaceae Isolated from Companion Animals in Europe (ComPath II Study). Vet. Microbiol. 2018, 216, 159–167. [Google Scholar] [CrossRef] [PubMed]
  43. Benaicha, H.; Barrijal, S.; Ezzakkioui, F.; Elmalki, F. Prevalence of PMQR Genes in E. coli and Klebsiella Spp. Isolated from North-West of Morocco. J. Glob. Antimicrob. Resist. 2017, 10, 321–325. [Google Scholar] [CrossRef] [PubMed]
  44. Pasom, W.; Chanawong, A.; Lulitanond, A.; Wilailuckana, C.; Kenprom, S.; Puang-Ngern, P. Plasmid-Mediated Quinolone Resistance Genes, Aac (6′)-Ib-Cr, QnrS, QnrB, and QnrA, in Urinary Isolates of Escherichia coli and Klebsiella pneumoniae at a Teaching Hospital, Thailand. Jpn. J. Infect. Dis. 2013, 66, 428–432. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Moulin-Schouleur, M.; Schouler, C.; Tailliez, P.; Kao, M.-R.; Brée, A.; Germon, P.; Oswald, E.; Mainil, J.; Blanco, M.; Blanco, J. Common Virulence Factors and Genetic Relationships between O18: K1: H7 Escherichia coli Isolates of Human and Avian Origin. J. Clin. Microbiol. 2006, 44, 3484–3492. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Chen, J.-W.; Huang, H.H.; Chang, S.-M.; Scaria, J.; Chiu, Y.-L.; Chen, C.-M.; Ko, W.-C.; Wang, J.-L. Antibiotic-Resistant Escherichia coli and Sequence Type 131 in Fecal Colonization in Dogs in Taiwan. Microorganisms 2020, 8, 1439. [Google Scholar] [CrossRef] [PubMed]
  47. Lee, M.Y.; Choi, H.J.; Choi, J.Y.; Song, M.; Song, Y.; Kim, S.-W.; Chang, H.-H.; Jung, S.-I.; Kim, Y.-S.; Ki, H.K.; et al. Dissemination of ST131 and ST393 Community-Onset, Ciprofloxacin-Resistant Escherichia Coli Clones Causing Urinary Tract Infections in Korea. J. Infect. 2010, 60, 146–153. [Google Scholar] [CrossRef] [PubMed]
  48. Cerquetti, M.; Giufrè, M.; García-Fernández, A.; Accogli, M.; Fortini, D.; Luzzi, I.; Carattoli, A. Ciprofloxacin-Resistant, CTX-M-15-Producing Escherichia coli ST131 Clone in Extraintestinal Infections in Italy. Clin. Microbiol. Infect. 2010, 16, 1555–1558. [Google Scholar] [CrossRef] [Green Version]
  49. Coque, T.M.; Novais, Â.; Carattoli, A.; Poirel, L.; Pitout, J.; Peixe, L.; Baquero, F.; Cantón, R.; Nordmann, P. Dissemination of Clonally Related Escherichia coli Strains Expressing Extended-Spectrum β-Lactamase CTX-M-15. Emerg. Infect. Dis. 2008, 14, 195–200. [Google Scholar] [CrossRef]
  50. Hong, J.S.; Song, W.; Park, H.-M.; Oh, J.-Y.; Chae, J.-C.; Jeong, S.; Jeong, S.H. Molecular Characterization of Fecal Extended-Spectrum β-Lactamase-and AmpC β-Lactamase-Producing Escherichia coli from Healthy Companion Animals and Cohabiting Humans in South Korea. Front. Microbiol. 2020, 11, 674. [Google Scholar] [CrossRef] [Green Version]
  51. Moon, D.-C.; Choi, J.-H.; Boby, N.; Kang, H.-Y.; Kim, S.-J.; Song, H.-J.; Park, H.-S.; Gil, M.-C.; Yoon, S.-S.; Lim, S.-K. Bacterial Prevalence in Skin, Urine, Diarrheal Stool, and Respiratory Samples from Dogs. Microorganisms 2022, 10, 1668. [Google Scholar] [CrossRef]
  52. Moon, D.C.; Choi, J.-H.; Boby, N.; Kim, S.-J.; Song, H.-J.; Park, H.-S.; Gil, M.-C.; Yoon, S.-S.; Lim, S.-K. Prevalence of Bacterial Species in Skin, Urine, Diarrheal Stool, and Respiratory Samples in Cats. Pathogens 2022, 11, 324. [Google Scholar] [CrossRef]
  53. CLSI. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; CLSI Supplement VET08; CLSI: Wayne, PA, USA, 2018. [Google Scholar]
  54. Sorlozano, A.; Gutierrez, J.; Jimenez, A.; de Dios Luna, J.; Martínez, J.L. Contribution of a New Mutation in ParE to Quinolone Resistance in Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates. J. Clin. Microbiol. 2007, 45, 2740–2742. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Tartof, S.Y.; Solberg, O.D.; Manges, A.R.; Riley, L.W. Analysis of a Uropathogenic Escherichia coli Clonal Group by Multilocus Sequence Typing. J. Clin. Microbiol. 2005, 43, 5860–5864. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Saitz, W.; Montero, D.A.; Pardo, M.; Araya, D.; De la Fuente, M.; Hermoso, M.A.; Farfán, M.J.; Ginard, D.; Rosselló-Móra, R.; Rasko, D.A. Characterization of Adherent-Invasive Escherichia coli (AIEC) Outer Membrane Proteins Provides Potential Molecular Markers to Screen Putative AIEC Strains. Int. J. Mol. Sci. 2022, 23, 9005. [Google Scholar] [CrossRef]
  57. Batchelor, M.; Threlfall, E.J.; Liebana, E. Cephalosporin Resistance among Animal-Associated Enterobacteria: A Current Perspective. Expert Rev. Anti. Infect. Ther. 2005, 3, 403–417. [Google Scholar] [CrossRef] [PubMed]
  58. Tamang, M.D.; Nam, H.-M.; Gurung, M.; Jang, G.-C.; Kim, S.-R.; Jung, S.-C.; Park, Y.H.; Lim, S.-K. Molecular Characterization of CTX-M β-Lactamase and Associated Addiction Systems in Escherichia coli Circulating among Cattle, Farm Workers, and the Farm Environment. Appl. Environ. Microbiol. 2013, 79, 3898–3905. [Google Scholar] [CrossRef] [Green Version]
  59. Pérez-Pérez, F.J.; Hanson, N.D. Detection of Plasmid-Mediated AmpC β-Lactamase Genes in Clinical Isolates by Using Multiplex PCR. J. Clin. Microbiol. 2002, 40, 2153–2162. [Google Scholar] [CrossRef] [Green Version]
  60. Tamang, M.D.; Seol, S.Y.; Oh, J.-Y.; Kang, H.Y.; Lee, J.C.; Lee, Y.C.; Cho, D.T.; Kim, J. Plasmid-Mediated Quinolone Resistance Determinants QnrA, QnrB, and QnrS among Clinical Isolates of Enterobacteriaceae in a Korean Hospital. Antimicrob. Agents Chemother. 2008, 52, 4159–4162. [Google Scholar] [CrossRef] [Green Version]
  61. Jacoby, G.A. AmpC β-Lactamases. Clin. Microbiol. Rev. 2009, 22, 161–182. [Google Scholar] [CrossRef] [Green Version]
  62. Kim, J.; Bae, I.K.; Jeong, S.H.; Chang, C.L.; Lee, C.H.; Lee, K. Characterization of IncF Plasmids Carrying the Bla CTX-M-14 Gene in Clinical Isolates of Escherichia coli from Korea. J. Antimicrob. Chemother. 2011, 66, 1263–1268. [Google Scholar] [CrossRef] [PubMed]
  63. Everett, M.J.; Jin, Y.F.; Ricci, V.; Piddock, L.J. Contributions of Individual Mechanisms to Fluoroquinolone Resistance in 36 Escherichia coli Strains Isolated from Humans and Animals. Antimicrob. Agents Chemother. 1996, 40, 2380–2386. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Antibiotics 12 00745 g001 550
Figure 1. PFGE patterns E. coli ST131 (A) and E. coli ST405 (B) isolated from diseased dogs and cats in Korea.
Figure 1. PFGE patterns E. coli ST131 (A) and E. coli ST405 (B) isolated from diseased dogs and cats in Korea.
Antibiotics 12 00745 g001
Antibiotics 12 00745 g002 550
Figure 2. Location of E. coli isolates collection cities in Korea.
Figure 2. Location of E. coli isolates collection cities in Korea.
Antibiotics 12 00745 g002
Table
Table 1. Cefovecin and enrofloxacin resistance in E. coli isolated from diseased dogs and cats during 2018–2019.
Table 1. Cefovecin and enrofloxacin resistance in E. coli isolated from diseased dogs and cats during 2018–2019.
AnimalsSamplesNo. of E. coli
Isolates		Resistance % (No. of Isolates)p-Value
CefovecinEnrofloxacinCefovecin and Enrofloxacin
DogsDiarrhea44617.9 (80) a,A22.2 (99) a,A11.2 (50) a,A0.192
Skin/ear9124.2 (22) b,A34.1 (31) b,A18.7 (17) b,A0.210
Urine6425.0 (16) b,A23.4 (15) a,A10.9 (7) a,A0.403
Genital948.5 (8) c,A14.9 (14) c,A5.3 (5) c,A0.421
Subtotal69518.1 (126) A22.9 (159) A11.4 (79) A0.542
CatsDiarrhea12812.5 (16) a,B14.1 (18) a,B8.6 (11) a,A0.999
Skin/ear425.0 (1) b,A0 (0) b,B0 (0) b,B̶
Urine40 (0) c,B0 (0) b,B0 (0) b,B̶
Genital50 (0) c,B0 (0) b,B0 (0) b,B̶
Subtotal14112.1 (17) B12.8 (18) B7.8 (11) A0.829
Total83617.1 (143)21.2 (177)10.8 (90)0.562
The values with different lowercase letters as superscript (a, b, or c) represent significant statistical differences among sample groups in the same species in the same column. The different uppercase letters as superscript (A or B) indicates a significant difference between species within the same column (p < 0.05). p-value denotes the statistical significance between cefovecin-resistant and enrofloxacin-resistant isolates.
Table
Table 2. Distribution of cefovecin- and enrofloxacin-resistant E. coli among different age groups of diseased dogs and cats.
Table 2. Distribution of cefovecin- and enrofloxacin-resistant E. coli among different age groups of diseased dogs and cats.
AnimalsAges
(Year)		Resistance % (No. of Isolates)
CefovecinEnrofloxacinCefovecin and Enrofloxacin
Dogs<1 (n = 69)17.4 (12) a,A26.1 (18) a,A14.5 (10) a,A
1–5 (n = 242)14.0 (34) a,A14.0 (34) b,A6.2 (15) b,A
6–10 (n = 164)16.5 (27) a,A22.6 (37) a,A11.6 (19) a,A
11–15 (n = 130)28.5 (37) b,A43.1 (56) c,A23.1 (30) c,A
>15 (n = 22)9.1 (2) c,A13.6 (3) b,A4.5 (1) b,A
Unknown (n = 68)20.6 (14)19.1 (13)5.9 (4)
Subtotal (n = 695)18.1 (126) A23.2 (161) A11.4 (79) A
Cats<1 (n = 51)7.8 (4) a,B7.8 (4) a,B2.0 (1) a,B
1–5 (n = 61)14.8 (9) b,A16.4 (10) b,A9.8 (6) b,A
6–10 (n = 8)0 (0) c,B0 (0) c,B0 (0) c,B
11–15 (n = 2)50.0 (1) d,B50.0 (1) d,B50.0 (1) d,B
>15 (n = 1)0 (0) c,B0 (0) c,B0 (0) c,B
Unknown (n = 18)16.7 (3)16.7 (3)16.7 (3)
Subtotal (n = 141)12.1 (17) B12.8 (18) B7.8 (11) A
Total (n = 836)17.1 (143)21.4 (179)10.8 (90)
The values with different lowercase letters as superscript (a, b, c, or d) represent significant differences among the groups in the same species in the same column and the different uppercase letters as superscript (A or B) indicate significant differences between different species within the same column (p < 0.05).
Table
Table 3. Distribution of ESBL/AmpC-producing E. coli isolated from diseased dogs and cats.
Table 3. Distribution of ESBL/AmpC-producing E. coli isolated from diseased dogs and cats.
ESBL/AmpC Gene% (No.) of Isolates
DogsCatsTotal
(n = 89)
Diarrhea
(n = 50)		Skin/Ear
(n = 16)		Urine
(n = 7)		Genital
(n = 5)		Subtotal
(n = 78)		Diarrhea
(n = 11)
blaCTX-M-3 + blaCMY-20 (0)0 (0)14.3 (1)0 (0)1.3 (1)0 (0)1.1 (1)
blaCTX-M-1520.0 (10)31.3 (5)0 (0)20.0 (1)20.5 (16)9.1 (1)19.1 (17)
blaCTX-M-15 + blaCMY-24.0 (2)0 (0)0 (0)0 (0)2.6 (2)0 (0)2.2 (2)
blaCTX-M-554.0 (2)0 (0)14.3 (1)0 (0)3.8 (3)0 (0)3.4 (3)
blaCTX-M-55 + blaCMY-22.0 (1)0 (0)14.3 (1)0 (0)2.6 (2)0 (0)2.2 (2)
blaCTX-M-1420.0 (10)43.8 (7)0 (0)0 (0)21.8 (17)36.4 (4)23.6 (21)
blaCTX-M-14 + blaCMY-22.0 (1)0 (0)0 (0)0 (0)1.3 (1)0 (0)1.1 (1)
blaCTX-M-6510.0 (5)2.0 (2)0 (0)20.0 (1)10.3 (8)9.1 (1)10.1 (9)
blaCMY-238.0 (19)6.3 (1)57.1 (4)60.0 (3)34.6 (27)45.5 (5)36.0 (32)
blaCMY-2 + blaDHA0 (0)6.3 (1)0 (0)0 (0)1.3 (1)0 (0)1.1 (1)
Table
Table 4. Mechanisms of quinolone resistance of E. coli isolates from dogs and cats.
Table 4. Mechanisms of quinolone resistance of E. coli isolates from dogs and cats.
Point Mutations within the QRDRPMQRNo. of
Isolates		Minimum Inhibition Concentration50 (MIC50) (mg/L)
gyrAparCENRMARCIPNALOFL
Dog isolates (n = 78)
S83LS80IqnrS + aac(6’)-Ib-cr132163225616
S83L, D87GE84K–132161625616
S83L, D87YS80I–1864323225632
S83L, D87NS80I–3464323225632
qnrB132161625616
qnrS33216825632
aac(6’)-Ib-cr264163225632
S83L, D87NS80I, E84G–232161625616
S80I, E84V–1364323225632
aac(6’)-Ib-cr364166425616
Cat isolates (n = 11)
S83LS80IqnrS164323225632
S83L, D87NS80I–764163225632
qnrS164323225632
S83L, D87YS80I–232161625616
CIP, ciprofloxacin; ENR, enrofloxacin; MAR, marbofloxacin; NAL, nalidixic acid; OFL, ofloxacin. MIC50, the concentration at which 50% of the isolates were inhibited.
Table
Table 5. MLST profiles ESBL/AmpC-producing E. coli isolated from diseased dogs and cats in Korea.
Table 5. MLST profiles ESBL/AmpC-producing E. coli isolated from diseased dogs and cats in Korea.
ST TypeNo. of IsolatesProvinceHospitalResistance Gene
DogCat
131160Seoul (n = 6), Busan (n = 4), Daegu (n = 3), Incheon (n = 1), Ulsan (n = 1), Gwangju (n = 1)H-2 (n = 1), H-4 (n = 2), H-5 (n = 1), H-7 (n = 2), H-10 (n = 1), H-11 (n = 1), H-18 (n = 1), H-24 (n = 1), H-25 (n = 3), H-26 (n = 1), H-28 (n = 1), H-30 (n = 1)blaCTX-M-14 (n = 5), blaCTX-M-15 (n = 5), blaCTX-M-65 (n = 4), blaCMY-2 (n = 2)
40583Seoul (n = 8), Incheon (n = 2), Daegu (n = 1)H-4 (n = 1), H-12 (n = 2), H-13 (n = 2), H-22 (n = 2), H-33 (n = 2), H-15 (n = 1), H-25 (n = 1)blaCMY-2 (n = 9), blaCTX-M-3 + blaCMY-2 (n = 1), blaCTX-M-15 (n = 1)
45781Seoul (n = 5), Incheon (n = 3), Gwangju (n = 1)H-30 (n = 2), H-13 (n = 1), H-17 (n = 1), H-18 (n = 1), H-19 (n = 1), H-27 (n = 1), H-32 (n = 1), Unknown (n = 1)blaCMY-2 (n = 5), blaCTX-M-15 (n = 3), blaCTX-M-15 + blaCMY-2 (n = 1)
3871Seoul (n = 3), Ulsan (n = 2), Daejeon (n = 1), Busan (n = 1), Gwangju (n = 1)H-1 (n = 1), H-6 (n = 1), H-7 (n = 1), H-22 (n = 1), H-25 (n = 2), H-28 (n = 1), H-29 (n = 1)blaCTX-M-14 (n = 6), blaCTX-M-15 (n = 2)
64853Seoul (n = 7), Busan (n = 1)H-13 (n = 2), H-11 (n = 1), H-16 (n = 1), H-20 (n = 1), H-23 (n = 1), H-24 (n = 1), H-25 (n = 1)blaCTX-M-14 (n = 4), blaCMY-2 (n = 3), blaCTX-M-15 (n = 1)
15550Seoul (n = 4), Gwangju (n = 1)H-2 (n = 1), H-12 (n = 1), H-16 (n = 1), H-20 (n = 1), H-34 (n = 1)blaCMY-2 (n = 3), blaCTX-M-14 (n = 1), blaCTX-M-15 (n = 1)
200350Seoul (n = 2), Daegu (n = 1), Busan (n = 1), Gwangju (n = 1)H-3 (n = 1), H-8 (n = 1), H-14 (n = 1), H-25 (n = 1), Unknown (n = 1)blaCMY-2 (n = 2), blaCTX-M-14 (n = 1), blaCTX-M-14 + blaCMY-2 (n = 1), blaCTX-M-55 (n = 1)
41040Seoul (n = 4)H-21 (n = 2), H-19 (n = 1), H-20 (n = 1)blaCMY-2 (n = 4)
22430Seoul (n = 2), Gwangju (n = 1)H-25 (n = 2), H-1 (n = 1)blaCMY-2 (n = 2), blaCTX-M-65 (n = 1)
119330Seoul (n = 1), Daejeon (n = 1), Ulsan (n = 1)H-6 (n = 1), H-13 (n = 1), H-28 (n = 1)blaCTX-M-55 (n = 2), blaCTX-M-14 (n = 1)
35411Seoul (n = 1), Busan (n = 1)H-9 (n = 1), H-23 (n = 1)blaCTX-M-15 (n = 1), blaCMY-2 (n = 1)
74420Incheon (n = 2)H-31 (n = 1), H-32 (n = 1)blaCTX-M-65 (n = 2)
3401Seoul (n = 1)H-17 (n = 1)blaCTX-M 14 (n = 1)
6910Seoul (n = 1)H-13 (n = 1)blaCTX-M 14 (n = 1)
10510Seoul (n = 1)H-23 (n = 1)blaCTX-M-15 + blaCMY-2 (n = 1)
16210Seoul (n = 1)H-25 (n = 1)blaCTX-M-65 (n = 1)
37210Incheon (n = 1)H-33 (n = 1)blaCTX-M-15 (n = 1)
45010Seoul (n = 1)H-22 (n = 1)blaCTX-M-55 + blaCMY-2 (n = 1)
101110Seoul (n = 1)H-15 (n = 1)blaCMY-2 (n = 1)
119610Seoul (n = 1)H-12 (n = 1)blaCMY-2 (n = 1)
215901Ulsan(n = 1)H-28 (n = 1)blaCTX-M-65 (n = 1)
224510Seoul (n = 1)H-15 (n = 1)blaCTX-M-55 + blaCMY-2 (n = 1)
451610Seoul (n = 1)H-13 (n = 1)blaCTX-M-14 (n = 1)
515010Gwangju (n = 1)H-1 (n = 1)blaCTM-M-15 (n = 1)
586910Gwangju (n = 1)H-1 (n = 1)blaCTX-M-15 (n = 1)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Choi, J.-H.; Ali, M.S.; Moon, B.-Y.; Kang, H.-Y.; Kim, S.-J.; Song, H.-J.; Mechesso, A.F.; Moon, D.-C.; Lim, S.-K. Prevalence and Characterization of Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolated from Dogs and Cats in South Korea. Antibiotics 2023, 12, 745. https://doi.org/10.3390/antibiotics12040745

AMA Style

Choi J-H, Ali MS, Moon B-Y, Kang H-Y, Kim S-J, Song H-J, Mechesso AF, Moon D-C, Lim S-K. Prevalence and Characterization of Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolated from Dogs and Cats in South Korea. Antibiotics. 2023; 12(4):745. https://doi.org/10.3390/antibiotics12040745

Chicago/Turabian Style

Choi, Ji-Hyun, Md. Sekendar Ali, Bo-Youn Moon, Hee-Young Kang, Su-Jeong Kim, Hyun-Ju Song, Abraham Fikru Mechesso, Dong-Chan Moon, and Suk-Kyung Lim. 2023. "Prevalence and Characterization of Extended-Spectrum β-Lactamase-Producing Escherichia coli Isolated from Dogs and Cats in South Korea" Antibiotics 12, no. 4: 745. https://doi.org/10.3390/antibiotics12040745

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop